Alcon Inc. (0A0D)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 55.68 |
|---|---|
| 52-week range | 48.08 – 79.00 |
| Return, 1 month / 3 months | +3.5% / +1.8% |
| Return, 1 year / 3 years | −6.0% / −18.9% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 26.0% |
| Worst drawdown (1 year) | -28.4% |
| Average daily value traded | 18.95M USD |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Alcon is an eye care company based in Switzerland that develops products for vision and eye health. It supplies surgical equipment and devices used by eye surgeons for procedures such as cataract and retinal surgery, and it makes contact lenses and lens care products. The company also offers pharmaceutical treatments, including eye drops, for conditions affecting the eyes. Its customers are mainly eye care professionals, hospitals, clinics and opticians around the world.
The shares are listed on the London Exchange in UK under the code 0A0D, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Alcon Inc. (0A0D) trades on the London Exchange in UK. It last closed at USD 55.68 on 21 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,956 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 6.0% and over the last three months it rose 1.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 41 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.2% | ||
| From 52-week high | -17.3% | ||
| Momentum | 41 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 1.8% | ||
| 6-month return | -7.4% | ||
| 12-month return, skipping the last month | -9.1% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.4% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 18.95M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.0% |
|---|---|
| 1 month | +3.5% |
| 3 months | +1.8% |
| 6 months | −7.4% |
| 1 year | −6.0% |
| 3 years | −18.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 55.84 / 57.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.19 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | CHF 0.2800 |
| 13 May 2025 | CHF 0.2800 |
| 14 May 2024 | CHF 0.2400 |
| 10 May 2023 | CHF 0.2100 |
| 3 May 2022 | CHF 0.2000 |
| 4 May 2021 | CHF 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.